Heron Therapeutics (HRTX) Cost of Revenue (2017 - 2026)

Heron Therapeutics (HRTX) has 10 years of Cost of Revenue data on file, last reported at $10.6 million in Q1 2026.

• Quarterly Cost of Revenue rose 25.79% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.5 million (up 12.59% YoY) and the FY2025 annual result came in at $41.3 million, up 6.98% from the prior year.
• Cost of Revenue slipped to $10.6 million in Q1 2026, from $11.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $20.2 million in Q2 2023 to a low of $8.4 million in Q1 2024.
• A 5-year average of $12.4 million and a median of $11.1 million in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 48.43% — and 2024, when it plunged 49.9%.
• Tracing HRTX's Cost of Revenue over 5 years: stood at $12.6 million in 2022, then slipped by 21.72% to $9.9 million in 2023, then grew by 3.47% to $10.2 million in 2024, then advanced by 8.71% to $11.1 million in 2025, then decreased by 4.33% to $10.6 million in 2026.
• The last three Cost of Revenue figures came in at $10.6 million (Q1 2026), $11.1 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.